BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to an anti-inflammatory composition, and more particularly to an anti-inflammatory composition containing, as an active ingredient, a compound represented by Formula 1 or a salt thereof.

Description of the Prior Art

Inflammations are common homeostatic functions in vivo, which are alarm signals against endogenous and exogenous antigens (bacterial, viral, parasitic infections and various stress signals in cells). These alarm signals are sensed by immune cells, inducing innate immunity and adaptive immunity, ultimately maintaining homeostasis of the cells. Thus, inflammatory responses are necessary to maintain a living body normally.

However, if such inflammatory responses occur excessively, biological tissues or organs at the site of inflammation do not maintain their original functions, and undesirable immune dysregulation occurs, leading to pain and fever, which are defined inflammatory diseases.

Excessive inflammatory responses to antigens may occur due to abnormalities in the affinity between immune cells (e.g., dendritic cells and T cells) and co-stimulatory receptor-ligand interaction. In particular, autoreactive T cells break down immune tolerance and cause a variety of inflammatory autoimmune diseases (rheumatic arthritis, Crohn's disease, lupus, nervous multiple sclerosis, etc.).

Thus, there is a need for potent anti-inflammatory agents to cope with these inflammatory diseases, which still constitutes the largest unmet need in the medical community.

The present inventors previously developed a novel compound exhibiting an excellent therapeutic effect against fibrosis (Korean Patent No. 10-1871166). In connection with this compound, the present inventors have conducted further studies and found that the developed compound can be involved in anti-inflammatory responses. Accordingly, the present inventors have conducted further studies on the possibility of the compound as an anti-inflammatory agent in earnest, and as a result, have found that the compound can actually exhibit a very excellent anti-inflammatory effect, thereby completing the present invention.

PRIOR ART DOCUMENTS

Patent Documents

Korean Patent No. 10-1871166

SUMMARY OF THE INVENTION

It is a main object of the present invention to provide an anti-inflammatory composition exhibiting an excellent inhibitory effect on inflammatory response.

Another object of the present invention is to provide a method of treating an inflammatory disease in a subject in need thereof.

In accordance with one aspect of the present invention, the present invention provides an anti-inflammatory composition containing, as an active ingredient, a compound represented by the Formula 1:



or a salt thereof,

wherein R1is C1-5alkyl, C5-6cycloalkyl, C5-6heterocycloalkyl, C6-12aryl or C5-6heteroaryl, where the C5-6heterocycloalkyl or C5-6heteroaryl each independently contain at least one heteroatom selected from the group consisting of oxygen and nitrogen; R2is hydrogen, ethyl, acetyl, acetoxy, carboxy, benzoyloxy or 3,4,5-trihydroxybenzoyloxy; R3is hydrogen, hydroxy, methyl, methoxy, acetoxy, carboxy or benzoyloxy; R4is hydrogen, hydroxy, methyl, methoxy, acetoxy, carboxy or benzoyloxy; and R5is hydrogen, hydroxy, methyl, methoxy, acetoxy, carboxy or benzoyloxy.

In the composition of the present invention, R1is preferably methyl, ethyl, cyclopentyl, cyclohexyl or phenyl.

In the composition of the present invention, preferably, R1is methyl; R2is hydrogen; R3is hydrogen, hydroxy or methoxy; R4is hydroxy or methoxy; and R5is hydrogen, hydroxy or methoxy.

In the composition of the present invention, the compound is preferably selected from the group consisting of Formula 2, Formula 3, Formula 4 and Formula 5:



or a salt thereof.

In the composition of the present invention, the composition is preferably a pharmaceutical composition, a quasi-drug composition, a food composition, a food additive composition, a feed composition, a feed additive composition, or a cosmetic composition.

In accordance with another aspect of the present invention, the present invention provides a method of treating an inflammatory disease in a subject in need thereof, comprising: providing a composition comprising, as an active ingredient, a compound represented by the Formula 1:



or a salt thereof,

wherein R1is C1-5alkyl, C5-6cycloalkyl, C5-6heterocycloalkyl, C6-12aryl or C5-6heteroaryl, where the C5-6heterocycloalkyl or C5-6heteroaryl each independently contain at least one heteroatom selected from the group consisting of oxygen and nitrogen; R2is hydrogen, ethyl, acetyl, acetoxy, carboxy, benzoyloxy or 3,4,5-trihydroxybenzoyloxy; R3is hydrogen, hydroxy, methyl, methoxy, acetoxy, carboxy or benzoyloxy; R4is hydrogen, hydroxy, methyl, methoxy, acetoxy, carboxy or benzoyloxy; and R5is hydrogen, hydroxy, methyl, methoxy, acetoxy, carboxy or benzoyloxy; and administering the composition to the subject, wherein the inflammatory disease is treated.

In the method of the present invention, R1is preferably methyl, ethyl, cyclopentyl, cyclohexyl or phenyl.

In the method of the present invention, preferably, R1is methyl; R2is hydrogen; R3is hydrogen, hydroxy or methoxy; R4is hydroxy or methoxy; and R5is hydrogen, hydroxy or methoxy.

In the method of the present invention, the compound is preferably selected from the group consisting of Formula 2, Formula 3, Formula 4 and Formula 5:



or a salt thereof.

In the method of the present invention, the composition is preferably a pharmaceutical composition, a quasi-drug composition, a food composition, a food additive composition, a feed composition, a feed additive composition, or a cosmetic composition.

In the method of the present invention, the inflammatory disease is preferably selected from the group consisting of inflammatory lung disease, inflammatory liver disease, inflammatory bowel disease, autoinflammatory disease, inflammatory central nervous system disease, inflammatory skin disease, and allergic inflammatory disease.

In the method of the present invention, the inflammatory disease is preferably selected from the group consisting of interstitial lung disease (ILD), non-alcoholic steatohepatitis (NASH), Crohn's disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, lupus, multiple sclerosis, Parkinson's disease, scleroderma, and psoriasis.

